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Disruption of Angiogenesis by PEX,
a Noncatalytic Metalloproteinase Fragment
with Integrin Binding Activity
integrin avb3 (Brooks et al., 1994a, 1994b, 1996; Fried-
lander et al., 1995). In fact, integrin avb3 was shown to
bind directly to the matrix metalloproteinase MMP-2
on the surface of invasive cells (Brooks et al., 1996),
suggesting a possible functional link between these
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MMPs are a family of zinc-dependent matrix-degrading10550 North Torrey Pines Road
La Jolla, California 92037 enzymes, which collectively are capable of degrading a
wide variety of ECM proteins (Mignatti and Rifkin, 1993;
DeClerck and Laug, 1996; Stetler-Stevenson, 1996).
Moreover, MMPs have been shown to contribute to theSummary
invasive behavior of many cell types. However, exten-
sive uncontrolled proteolysis may impede cellular inva-Angiogenesis depends on both cell adhesion and pro-
sion due todestruction of matrix components necessaryteolytic mechanisms. In fact, matrix metalloproteinase
for cell migration and survival (Stetler-Stevenson, 1996).2 (MMP-2) and integrin avb3 are functionally associ-
Therefore, it is likely that a tightly regulated mechanismated on the surface of angiogenic blood vessels. A
exists to control proteolysis during the angiogenicfragment of MMP-2, which comprises the C-terminal
cascade.hemopexin-like domain, termed PEX, prevents this en-
Recently, a number of angiogenesis inhibitors havezyme binding to avb3 and blocks cell surface collagen-
been identified as cryptic regions or fragments of intactolytic activity. PEX blocks MMP-2 activity on the chick
molecules, which, in pure form, possess the capacitychorioallantoic membrane where it disrupts angiogen-
to block angiogenesis (Tolsma et al., 1993; Volpert etesis and tumor growth. Importantly, a naturally oc-
al., 1995; O'Reilly et al., 1997). In this report, we providecurring form of PEX can be detected in vivo in conjunc-
evidence that the noncatalytic C-terminal hemopexin-tion with avb3 expression in tumors and during
like domain of MMP-2, PEX, can interact with integrindevelopmental retinal neovascularization. Levels of
avb3 and thereby block MMP-2 binding to this integrin.PEX in these vascularized tissues suggest that it inter-
PEX appears as a naturallyoccurring MMP-2 breakdownacts with endothelial cell avb3 where it serves as a
product that can inhibit cell associated collagenolyticnatural inhibitor of MMP-2 activity, thereby regulating
activity both in vitro and in vivo. Levels of PEX detectedthe invasive behavior of new blood vessels.
within tissues in vivo suggest it may be an important
regulator of protease activity during angiogenesis and
vasculogenesis. Moreover, a recombinant form of PEXIntroduction
blocks angiogenesis and tumor growth in vivo, providing
a potentially novel therapeutic approach for diseasesAngiogenesis represents an invasive cellular process
associated with neovascularization.that requires the functional activity of a wide variety of
molecules, including growth factors, extracellular matrix
(ECM) proteins, adhesion receptors, and proteolytic en- Results
zymes (Ingber and Folkman, 1989; Blood and Zetter,
1990; Brooks et al., 1994a, 1995; Folkman and D'Amore, The MMP-2 Hemopexin Domain (PEX) Binds to
1996). During angiogenesis, the coordinated regulation Integrin avb3 and Disrupts the Interaction
of these proteins leads to endothelial cell proliferation, between MMP-2 and avb3
matrix remodeling, cellular migration/invasion, and even- MMP-2 can be localized on the surface of invasive cells
tually, differentiation (D'Amore and Thompson, 1987; based on its ability to bind integrin avb3 (Brooks et
Grant et al., 1989; Senger, 1996). Thus, the physiological al., 1996). This interaction depends on the C-terminal
control of angiogenesis is dependent on the proper tem- hemopexin-like domain of MMP-2, since a truncation
poral and spatial balance of activators and inhibitors mutant lacking this domain failed to localize to the sur-
present within the vascular microenvironment (Auer- face of avb3-bearing cells. This suggests that a fragment
bach and Auerbach, 1994; Hanahan and Folkman, 1996). of MMP-2, which contains the hemopexin domain, may
However, the molecular mechanisms controlling this be capable of interfering with MMP-2 binding to this
delicate balance remain unclear. Importantly, neovascu- receptor. To examine this possibility,we prepared MMP-
larization, when uncontrolled, can contribute to a num- 2-derived recombinant bacterial fusion proteins. As
ber of pathological processes including diabetic reti- shown in Figure 1A, the fusion protein termed PEX en-
nopathy, rheumatoid arthritis, as well as tumor growth compasses the C-terminal hemopexin-like domain of
and metastasis (Blood and Zetter, 1990; Brooks et al., MMP-2 (amino acids 445±637), while a second fusion
1994b; Folkman, 1995). protein, termed FHEX, contains the hemopexin domain,
We recently reported that angiogenesis depends on hinge region, as well the third of three fibronectin type
specific endothelial cell adhesive events mediated by II repeats (amino acids 292±637).
To determine whether these MMP-2-derived frag-
ments could bind to avb3, this receptor was immobilized³To whom correspondence should be addressed.
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MMP-2 binding to avb3, while this quantity of FHEX did
not (Figure 1C). These data demonstrate that PEX can
interact with avb3 and prevent MMP-2 binding to this
integrin. Interestingly, when this hemopexin domain is
expressed in the context of the hinge region and an
adjacent fibronectin type II repeat (FHEX), its ability to
interact with avb3 is significantlydiminished. These find-
ings suggest that the hemopexin-like domain of MMP-2
can interact with avb3 and that this interaction may be
structurally influenced by regions outside the hemo-
pexin domain. In any event, FHEX proved to be a useful
control fusion protein for these studies as it contains
the hemopexin domain yet fails to significantly interact
with avb3.
PEX Blocks Cell-Mediated Collagen Degradation
Expression of avb3 on the surface of invasive cells can
facilitate cell surface localization of MMP-2 and thus
potentiate cell-mediated collagen degradation (Brooks
et al., 1996). To examine the effects of PEX on cell-
directed collagenolytic activity, we examined avb3-
bearing melanoma and endothelial cells, which produce
only minimal quantities of endogenous MMP-2 (data not
shown). CS-1 melanoma cells lack expression of integrin
avb3. These cells were transfected with a cDNA encod-
ing the b3 integrin subunit that facilitates functional ex-
pression of avb3 (Filardo et al., 1995). Full-length MMP-2
was then incubated with either avb3-negative CS-1 cells
or CS-1 cells that express avb3, in the presence or
absence of either PEX or FHEX. As shown in Figure 2A,
addition of MMP-2 to avb3-expressing CS-1 cells, but
not control cells, resulted in a dramatic increase in colla-
genolytic activity that was inhibited by the addition of
PEX, but not FHEX. In contrast, both avb3-negative and
avb3-positive CS-1 cells showed only minimal collagen-
olytic activity in the absence of exogenously added
MMP-2. These findings demonstrate that expression of
integrin avb3 on CS-1 melanoma cells promotes cell
Figure 1. PEX Interacts with avb3 and Disrupts Intact MMP-2 Bind- surface collagenolytic activity, which can be blocked by
ing to avb3 the noncatalytic hemopexin-like domain of MMP-2.
(A) Schematic representation of MMP-2. GST fusion proteins were During the invasive stage of angiogenesis, endothelial
designed to encompass regions within the C-terminal portion of cells typically express high levels of avb3 (Brooks et al.,
avian MMP-2. The full-length avianMMP-2 is composed of a number
1994a). Therefore, we examined an endothelial cell lineof functional domains including a propeptide sequence (Pro), the
expressing integrin avb3. These cells were subjected tocatalytic active domain (catalytic), three fibronectin type II repeats
several rounds of negative fluorescence-activated cell(FN Type II), a zinc binding domain (Zn1), the hinge region (hinge),
and the C-terminal hemopexin/vitronectin-like domain (hemopexin). sorting (FACS), facilitating the selection of a stable avb3
Fusion protein PEX encodes the hemopexin-like domain alone negative nonclonal endothelial cell variant. Importantly,
(amino acids 445±637), while fusion protein FHEX encodes the he- neither the avb3-positive nor the avb3-negative cells
mopexin domain as well as the hinge region and the third of the three produced significant levels of endogenous MMP-2, and
fibronectin type II repeats, encompassing amino acids 292±637.
both cell variants showed identical integrin profiles with(B) Dose response binding curve for fusion proteins PEX and FHEX
the exception of integrin avb3 (data not shown). Asto purified integrin avb3. The recombinant fusion proteins PEX and
shown in Figure 2B, only the avb3-bearing endothelialFHEX were radioiodinated and allowed to interact with immobilized
integrin avb3 in a purified receptor binding assay as described in cells showed a significantly increased collagenolytic ac-
the Experimental Procedures. tivity after incubation with exogenously added MMP-2.
(C) Radiolabeled full-length MMP-2 was allowed to interact with This cell-mediated collagenolytic activity could be re-
purified immobilized integrin avb3 in the presence or absence of
duced by preincubation of these cells with PEX but was100-fold molar excess of unlabeled PEX or FHEX. Data represents
only minimally affected by FHEX (Figure 2B). This sug-the mean 6 standard error from triplicate wells.
gests that addition of PEX to avb3-expressing cells can
prevent MMP-2 binding to the cell surface, thereby de-
onto microtiter wells and allowed to interact with radiola- creasing cell-mediated collagenolytic activity.
beled PEX or FHEX. As shown in Figure 1B, PEX readily
bound to integrin avb3 in a dose-dependent manner, Detection of Autocatalytically Derived PEX
while FHEXshowed only minimalbinding. The specificity In Vitro and In Vivo
of this interaction was further demonstrated since a 100- MMP-2 activity has been suggested to play a critical
role in angiogenesis since inhibitors of this enzyme blockfold molar excess of unlabeled PEX competed for intact
MMP Fragment Binds Integrin, Disrupts Angiogenesis
393
Figure 3. Autocatalysis Yields C-terminal Hemopexin Domain,
Figure 2. Recombinant PEX Blocks Cell Surface Collagenolytic which Disrupts Binding of Intact MMP-2 to Integrin avb3
Activity In Vitro
MMP-2 processing was examined in vitro in response to organomer-
avb3-positive and -negative variants of CS-1 melanoma cells and curial activation and in vivo via tumor-associated degradation of
ECV304 endothelial cells were isolated as described in the Experi- endogenous MMP-2. Autocatalytically derived C-terminal fragment
mental Procedures. These cell variants of both cell types produce was purified and assessed for its ability to inhibit interaction be-
minimal quantities of endogenous MMP-2. Full-length recombinant tween the full-length enzyme and integrin avb3.
MMP-2was allowed to bind to these cells in thepresence or absence (A) Intact purified chick MMP-2 was activated with APMA, and equal
of either PEX or FHEX, followed by washing to remove unbound quantities of starting material or activated MMP-2 were electropho-
enzyme and seeding into microtiter wells coated with [3H]-collagen resed and analyzed by Western blotting with an anti-MMP-2 poly-
type IV. Substrate degradation was assessed as the release of ra- clonal antibody.
diolabled material into the culture medium after 36 hr. Data bars (B) ELISA determination of autocatalytically derived C terminus ef-
represent themean 6 standard error of corrected cpm from triplicate fect on MMP-2 binding to integrin avb3. Full-length purified MMP-2
wells. Cell-mediated collagen degradation by (A) CS-1 melanoma was allowed to interact with integrin avb3 in the presence orabsence
cells or (B) ECV304 endothelial cells. In a typical experiment, the of increasing concentrations of C terminus purified from activated
collagenase activity was 2±3 fold over background levels. intact enzyme. Data points indicate the background-corrected
mean 6 standard errors from triplicate wells.
neovascularization (Moses et al., 1990; Galardy et al.,
1994; Anand-Apte et al., 1997). Activation of MMP-2 recombinant PEX. Importantly, the accumulation of the
C-terminal fragment increased significantly after activa-depends on its proteolytic processing. In fact, proteo-
lytic removal of theN-terminal 80±amino acid prodomain tion with APMA (data not shown).These findings demon-
strate that PEX is a natural breakdown product of thisof MMP-2 leads to the generation of a 62 kDa active
form (Ward et al., 1991; Fridman et al., 1992; Strongin enzyme.
To establish whether an autocatalytically generatedet al., 1995), which can be processed further to a 43 kDa
fragment with gelatinolytic activity and a noncatalytic 29 C terminus of MMP-2 might display similar properties to
those observed for the recombinant form of this protein,kDa C-terminal fragment, which comprises the hemo-
pexin-like domain (Howard et al., 1991). As shown in solid-phase receptor binding analyses were performed.
As shown in Figure 3B, the MMP-2 C terminus derivedFigure 3A, purified MMP-2 can be activated in vitro with
p-aminophenyl-mercuric acetate (APMA), which leads from the intact purified enzyme inhibits the interaction
between avb3 and MMP-2 in a dose-dependent manner.to the generation of the 62 kDa active species and the
C-terminal fragment as detected by immunoblotting. In The specificity of this interaction was further demon-
strated since neither full-length MMP-9 nor glutathione-addition, the 43 kDa gelatinolytic fragment can be de-
tected by zymography, but due to its rapid processing S-transferase at equimolar concentrations interfered
with intact MMP-2 binding to avb3 (data not shown).this fragment appears only as a transient breakdown
product (data not shown). Interestingly, the C-terminal
fragment as well as the proenzyme and active forms Naturally Occurring PEX Accumulation In Vivo
Depends on Expression of avb3of MMP-2 were found in media from bFGF-stimulated
human umbilical vein endothelial cells (HUVECs) as de- To establish whether these MMP-2 fragments can be
generated in an avb3-dependent manner in vivo, CS-1tected by immunoblotting with MAb TV88 directed to
Cell
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melanoma tumors, which either express or lack avb3,
were grown on the chorioallantoic membranes (CAMs)
of chick embryos and examined for the presence of
MMP-2 and its proteolytic fragments. Lysates from
these tissues were then examined by Western blot anal-
ysis with MAb TV88, which recognizes the chick, human,
or mouse C-terminal hemopexin-like domain. As shown
in Figure 4A, whereas the host-derived proenzyme and
active species were present in both tumor variants, sig-
nificant quantities of PEX were only observed in avb3-
bearing CS-1 tumor tissues. These findings show that
the C-terminal hemopexin domain of MMP-2 corre-
sponding to PEX can be generated in vivo in an avb3-
dependent manner.
To determine whether PEX accumulation associated
with the avb3-bearing tumors may be linked to a change
in their angiogenic response, CS-1 tumors lacking or
expressing avb3 were grown for 7 days on the CAM of
10-day-old embryos and photographed. As shown in
Figure 4B, CS-1 tumors develop an extensive array of
both large and small blood vessels. In contrast, avb3-
bearing tumors are considerably smaller and show a
reduced number of microvessels compared to CS-1 tu-
mors lacking avb3. Therefore, not only does PEX accu-
mulation depend on local expression of avb3, but its
appearance is associated with decreased vasculariza-
tion associated with these tumors.
PEX Accumulates during the Development
of Retinal Blood Vessels
Murine retinal blood vessel development is initiated
shortly before birth and proceeds for approximately 2
weeks postnatally (Friedlander et al., 1996). During this
period, avb3 is expressed on these vessels. In fact,
antagonists of avb3 disrupt neovascularization in these
tissues (Friedlander et al., 1996). Extensive invasion of
these superficial blood vessels occurs during the first
Figure 4. Naturally Occurring PEX Accumulation In Vivo Depends4±6 days postnatally and is followed by vessel matura-
on Expression of Integrin avb3tion and formation of a secondary vascular network as
(A) Three groups of three separate randomly selected avb3-positivewas previously described in the rat (Stone et al., 1995).
and -negativeCS-1 tumors grown on the chick CAM were harvested,To establish whether the development and maturation
lysed, and pooled before electrophoresis (50 mg/lane from eachof these blood vessels was associated with the accumu-
pool) and immunoblotting with the anti-PEX MAb TV88 as described
lation of PEX, retinas of varying postnatal age were re- in the Experimental Procedures. Intact avian MMP-2 was coelectro-
moved, lysed, and analyzed for the expression of PEX phoresed as a control (CTRL).
by Western blot using MAb TV88. As shown in Figure (B) Photomicrographic demonstration of the gross morphology of
avb3-negative and positive-CS-1 tumors grown on the chick CAM.4C, PEX can be detected during the invasive stage of
Tumor cells (5 3 106) were implanted on 10-day embryos and grownneovascularization at postnatal days 2 and 4, where it
for 7 days prior to harvesting and photographing at 103 magnifica-shows a 5-fold increase over the levels detected in the
tion on an Olympus stereomicroscope.
adult retina. However, when blood vessels begin to ma- (C) Retinas were harvested from postnatal mice at days 2, 4, 6, 8,
ture in these tissues by days 5-6, the relative level of and 11 or adult mice, and lysed, and 25 mg of each lysate was
PEX increases to 13.5 fold over the level found in adult separated by SDS PAGE on 10% gels. Proteins were electroblotted
and probed with MAb TV88 directed to PEX. The immunoreactiveretina and shows a steady decline from day 8 to 11 as
band corresponding to PEX was subjected to densitometric analysisneovascularization subsides (relative density 12 and 9.5,
and the relative density compared to PEX found in the adult retina.respectively). These findings demonstrate that PEX ac-
The kinetics of vessel invasion and maturation are depicted as bars
cumulates during vessel invasion and reaches a maxi- below the figure.
mal level during the maturation stage of retinal neovas-
cularization, suggesting it acts as a negative regulator
of the invasive stage of retinal neovascularization. regulate the invasive behavior of newly sprouting blood
vessels. The fact that PEX can bind to avb3 and prevent
MMP-2 collagenolytic activity in vitro raises the possibil-PEX Disrupts Angiogenesis In Vivo
The accumulation of PEX in avb3-bearing tumors or ity that this fragment may be able to impact angiogen-
esis in vivo. To test this hypothesis, angiogenesis wasduring retinal neovascularization suggests that it may
MMP Fragment Binds Integrin, Disrupts Angiogenesis
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Figure 5. PEX Blocks Angiogenesis and Ac-
cumulates to Physiologically Relevant Levels
In Vivo
Angiogenesis was induced on the CAMs of
10-day-old chick embryos using a 5 mm filter
disc saturated with recombinant bFGF placed
on an area of the CAM that is relatively devoid
of preexisting blood vessels. Equimolar (2
nmol) amounts of recombinant PEX or FHEX
were added topically to the filter disc CAMs
for 3 consecutive days. The CAM tissue asso-
ciated with the filter disc was removed and
photographed at 103 on an Olympus stereo-
microscope.
(A) Representative examples of filter disc as-
sociated±CAM tissues taken from a typical
experiment.
(B) Quantification of a typical angiogenesis
experiment was accomplished by counting
blood vessel branch points in blinded manner.
(C) Dose-response effects of PEX and FHEX
on angiogenesis as determined by enumera-
tion of branch points. Data points represent
mean 6 standard error from 5 to 8 embryos
per condition.
(D) Quantitative determination of endoge-
nous PEX in developing retinal tissue. Mouse
retinas were dissected on postnatal day 5,
lysed, and densitometrically compared to
known amounts of recombinant PEX by
Western blotting using the TV88 MAb as de-
scribed in the Experimental Procedures. As
shown, linear interpolation against a plot of
recombinant PEX standards yielded a value
of 109 pmol/mg of tissue extract for a densi-
tometric reading of 62 units and a threshold
of detection of less than 10 ng of antigen
(x-intercept). Inset, photomicrographic dem-
onstration of recombinant PEXstandards and
the band observed in 50 mg of postnatal day
6 retinal lysate.
induced with bFGF on the CAMs of 10-day chick em- levels of PEX found in extracts of retinal and tumor
tissue were quantitatively determined by densitometricbryos, and PEX or FHEX was either added topically to
the CAMs or injected systemically into these embryos. comparison of band intensities. The level of PEX in the
postnatal day 5±6 murine retina was approximately 109As shown in Figure 5, angiogenesis was induced within
these CAMs directly below 5 mm filter discs coated pmol/mg of extracted tissues (Figure 5D). Postnatal
days 5±6 represent the time retinal blood vessels ceasewith bFGF. This angiogenic response was specifically
disrupted by addition of PEX but not FHEX (Figure 5A). invading and begin to mature. In addition, avb3-bearing
CS-1 tumors contained PEX at 21 pmol/mg, while CS-1In fact, addition of 2 nmol of PEX resulted in .93%
decrease in the angiogenic index as determined by enu- tumors lacking avb3 contained approximately 1 pmol/
mg (data not shown). The increased PEX in the avb3-merating the visible blood vessel branch points within
the area of the filter discs (Figure 5B). Furthermore, this containing tumors correlated with a decrease in mi-
crovessel density in these tumors compared to CS-1antiangiogenic effect was dose-dependent (Figure 5C).
tumors, which fail to express avb3 and do not produce
significant levels of PEX (Figure 4B). We next addedPhysiologically Active Levels of PEX
Can Be Detected at Sites of recombinant PEX to CAMs at a concentration shown to
produce .90% inhibition of bFGF-induced angiogen-Neovascularization In Vivo
To establish whether the levels of PEX observed in vivo esis (Figure 5C). Extracts of these tissues were shown
to contain approximately 750 pmol of PEX/mg tissueduring neovascularization of tumors and in the devel-
oping retina reach physiological levels sufficient to influ- as determined above. However, based on the dose-
dependent effects of PEX on CAM angiogenesis as de-ence blood vessel formation or remodeling, PEX was
quantified in extracts of these tissues by Western blot picted in Figure 5C, half-maximal inhibition of angiogen-
esis was achieved with the input of 10-fold less PEX,analysis using MAb TV-88 directed to PEX. A standard
curve for PEX was obtained by immunoblotting known (i.e., 75 pmol/mg tissue). As shown in Figure 5D, this is
within the range of PEX detected in the retinal tissue onamounts of recombinant PEX (Figure 5D, inset), and the
Cell
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was blocked by the addition of the metalloproteinase
inhibitor 1:10 phenanthroline (data not shown). In addi-
tion, the serine protease inhibitor aprotinin, present in
the lysis buffer, failed to impact this activity (Figure 6A).
Importantly, addition of PEX but not FHEX to these
CAMs during angiogenesis blocked the appearance of
the 62 kDa gelatinolytic band (Figure 6A) as well as
the associated collagenolytic activity (Figure 6B). PEX
blocked this MMP-2 activity at 24, 48, and 72 hr after
bFGF stimulation, even though new blood vessel forma-
tion in these tissues was not observed for approximately
48 hr after addition of bFGF. These findings suggest
that the antiangiogenic effects of PEX are associated
with its ability to block collagenolytic activity in vivo.
Significant accumulation of this noncatalytic C-terminal
domain may ultimately slow ongoing angiogenesis by
reducing collagenolytic activity, thereby providing a
negative feedback mechanism to limit neovasculariza-
tion under certain physiological conditions.
PEX Disrupts Tumor Growth In Vivo
Angiogenesis contributes to the growth and dissemina-
tion of malignant tumors. Therefore, we examined the
potential antitumor activity of recombinant PEX on avb3
negative CS-1 tumors grown on the CAMs of 10-day-
old chick embryos. Embryos were injected systemically
with either PEX or FHEX 24 hr after tumors were im-Figure 6. PEX Inhibits MMP-2 Activity In Vivo
planted onto the CAMs. As shown in Figures 7A and(A) Equal amounts (25 mg) of total CAM lysates prepared at 24, 48,
7B, PEX significantly inhibited the growth of these tu-and 72 hr after bFGF stimulation were analyzed by gelatin zymogra-
mors (p , 0.001, by Student's t test), while FHEX hadphy. The upper gelatinolytic band represents the 72 kDa ProMMP-2
species while the lower gelatinolytic band represents the 62 kDa little if any effect. To establish whether the antitumor
active form of MMP-2. effects observed were related to the ability of PEX to
(B) Equal amounts of total CAM lysates prepared at 24, 48, and 72 interfere with tumor-induced angiogenesis, bloodvessel
hr after bFGF stimulation were analyzed for their ability to degrade
counts were determined in cross sections of tumorsnative type IV collagen. Data bars represent the mean 6 standard
from animals treated with or without PEX. As shown inerror of cpm released into the culture medium of triplicate wells
Figure 7C, PEX produced a 45% decrease in blood ves-after 36 hr of incubation. The MMP-2 collagenase activity was typi-
cally 2±3 fold over background levels. sel density in these tumors relative to those treated with
FHEX or PBS. Importantly, PEX had no effect on the in
vitro growth rate of either avb3-positive or -negative
day 5 (109 pmol/mg tissue), when the invasive stage of
CS-1 tumor cells (data not shown), providing further
neovascularization gives way to blood vessel matura-
support for the notion that the effects of PEX on these
tion. These findings suggest that PEX accumulates dur-
tumors are due to its antiangiogenic activity.
ing neovascularization to levels that are physiologically
relevant to influence blood vessel invasion, growth, and/
or remodeling. Discussion
MMP-2 localizes in a proteolytically active form on thePEX Blocks Activation and Enzymatic
Activity of MMP-2 In Vivo surface of invasive cells based on its ability to bind
integrin avb3. Moreover, this interaction depends on theTo address the possible mechanism by which PEX im-
pacts the invasive behavior of blood vessels, we exam- C-terminal hemopexin-like domain of MMP-2, since a
truncation mutant lacking this domain failed to interactined the effects of PEX on MMP-2 enzymatic activity
during angiogenesis in vivo, since this fragment blocked with avb3 (Brooks et al., 1996). Therefore, we proposed
that this functional cooperation between MMP-2 andcell-mediated collagenolytic activity in vitro (Figure 2).
Lysates of angiogenic CAM tissues were analyzed for avb3 facilitates invasive cell behavior by localizing pro-
teolytic activity to discrete regions on the cell surface,MMP-2 activity by both gelatin zymography and colla-
gen degradation. As shown in Figure 6A, bFGF in- thereby potentiating angiogenesis and tumor metasta-
sis (Brooks et al., 1996).duced activation of MMP-2 in these CAM tissues within
24 hr as measured by the appearance of the 62 kDa In this report, evidence is provided that PEX blocks
MMP-2 binding to avb3, resulting in a loss of cell-associ-gelatinolytic band. This 62 kDa band was confirmed to
be active MMP-2 by Western blot analysis (data not ated collagenolytic activity. These findings are consis-
tent with previously reported results indicating that theshown). The appearance of the 62 kDa active MMP-2
species was associated with increased collagen degra- hemopexin domain of MMP-2 prevents cell-mediated
MMP-2 activation (Strongin et al., 1993; Zucker et al.,dation in these tissues (Figure 6B), and this collageno-
lytic activity was metalloproteinase-dependent since it 1995; Foda et al., 1996). Interestingly, the ability of
MMP Fragment Binds Integrin, Disrupts Angiogenesis
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Figure 7. Effects of PEX and FHEX on Tumor
Growth In Vivo
Single cell suspensions of 3 3 106 avb3-nega-
tive CS-1 tumor cells were applied to the
CAMs of 10-day-old chick embryos. The em-
bryos were injected intravenously with equi-
molar quantities of either recombinant PEX
or FHEX 24 hr later. Tumors were allowed to
grow for a total of 6 days, followed by resec-
tion and wet weight determination.
(A) Representative examples of CS-1 mela-
noma tumors after control (PBS) injections or
treatment with either PEX or FHEX.
(B) Quantification of CS-1 melanoma tumor
weights. Bars represent mean tumor weights
from each experimental condition.
(C) Blood vessel counts from sections of CS-1
tumors treated with PBS or equimolar quanti-
ties of PEX or FHEX as described above.
Quantitation was performed in a blind fash-
ion, anddata barsrepresent the mean 6 stan-
dard error of at least 10 high-power fields
from each tumor group.
MMP-2 to bind to avb3 appears to be distinct from can be controlled, thereby regulating cellular invasion
events (Stetler-Stevenson et al., 1993; Stetler-Steven-other avb3-directed ligands, since MMP-2 lacks an RGD
sequence (Aimes et al., 1994) commonly found in ligands son, 1996).
Initial activation of MMP-2 is associated with proteo-for this receptor (Cheresh et al., 1989). At present, it
is not clear whether the C-terminal domain of MMP-2, lytic processing of the intact 72 kDa enzyme, leading to
the autocatalytic removal of the 80 amino acid prodo-termed PEX, is the only region of this enzyme that binds
avb3. However, MMP-2 binding to avb3 may depend on main, resulting in the 62 kDa active form (Ward et al.,
1991; Fridman et al., 1992; Strongin et al., 1995). It hasa tertiary structure since the larger C-terminal fragment,
termed FHEX, containing PEX as well as the flexible been suggested that in the absence of TIMP-2, this
active 62kDa form can be further processed to a 43 kDahinge domain and the third type II fibronectin repeat,
binds poorly to avb3. active species resulting from autocatalytic removal of
the 29 kDa hemopexin-like domain (Howard et al., 1991).Systemic administration of recombinant PEX blocked
collagenolytic activity in vivo, leading to a significant This C-terminal domain of MMP-2 appears to be the
same fragment that we identified as PEX as detectedreduction in thegrowth of CS-1 melanoma tumors grown
on the CAMs of chick embryos. This effect was related with MAb TV88 generated to the recombinant form of
this molecule. This antibody served to identify PEX into its capacity to significantly reduce angiogenesis in
these tumors. Importantly, these CS-1 melanoma tu- extracts of avb3-bearing CS-1 tumors and during retinal
blood vessel development, suggesting that avb3 ex-mors lack functional expression of integrin avb3 and
produce little if any endogenous MMP-2 (Brooks et al., pression contributes to the generation of this fragment
in vivo.1996), providing further evidence that the observed inhi-
bition of tumor growth is due to the suppression of Integrin avb3 expression on tumors was associated
with decreased angiogenesis and, accordingly, thetumor-associated angiogenesis. In fact, PEX did not in-
fluence the growth rate of these cells in vitro, supporting production of PEX to levels within the physiological
range required for angiogenesis inhibition. Importantly,the notion that the antitumor activity of PEX is due to
its antiangiogenic effects. Moreover, since PEX blocks PEX was shown to accumulate in retinal membranes
undergoing developmental neovascularization. Whilecollagenolytic activity both in vitro and in vivo, it is likely
that the antiangiogenic effects of PEX are related to its PEX was first detected during the invasive stage of reti-
nal neovascularization, its level reached a maximum dur-ability to block collagenolytic activity. This contention
is supported by previous studiesdemonstrating the abil- ing the maturation stage of new blood vessels and was
only minimally detectable in the adult retina. The factity of naturally occurring tissue inhibitors of metallopro-
teinase (TIMPs) to inhibit angiogenesis (Moses et al., that PEX blocks avb3-directed MMP-2 activity and dis-
rupts angiogenesis suggests that its accumulation dur-1990; Galardy et al., 1994; Anand-Apte et al., 1997). In
fact, the balanced expression of both TIMPs and MMPs ing blood vessel maturation would allow it to provide a
feedback mechanism to prevent inappropriate bloodcould provide a mechanism whereby matrix degradation
Cell
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Construction of Chick MMP-2 GST Fusion Proteinsvessel sprouting. In fact, the levels of PEX detected in
GST fusion proteins were constructed using primers based on thethese tissues are well within the concentration range
published avian MMP-2 sequence (Aimes et al., 1994). A singledetected in treatedCAMs where angiogenesis was mea-
antisense primer specific for the carboxy-terminal nucleotides 1912±
surably decreased. 1932 was engineered to contain an internal EcoR1 site (59-ATTGAAT
While avb3 may directly contribute to activation of TCTTCTACAGTTCA-39) and utilized for both PEX and FHEX. Sense
primers were engineered with internal BamH1 sites and encodeMMP-2 and generation of PEX, recent studies suggest
translation start sites at 445 (PEX; 59-CTCGGATCCTCTGCAAGCthat activation of MMP-2 can be mediated by specific
ACG-39) or 292 (FHEX; 59-GTGGGATCCCTGAAGACTATG-39). A full-transmembrane metalloproteinases or MT-MMPs (Sato
length MMP-2 cDNA was generated from chick CAM tissue by RT-et al., 1994; Caoet al., 1996; Fodaet al., 1996). Therefore,
PCR and used as a template for amplification of PEX and FHEX.
it is possible that MMP-2 binds to MT-MMP on the cell Products were digested and ligated into pGEX-3X plasmid (Phar-
surface and becomes partially activated whereby it then macia Biotech, Uppsala, Sweden), and GST fusion proteins were
purified from IPTG-induced log phase bacterial cultures containingbecomes capable of binding avb3. This is an attractive
these constructs on Sepharose 4B-coupled glutathione beadshypothesis since it suggests that only the active form
(Pharmacia Biotech). Beads were washed extensively and immobi-of MMP-2 would bind avb3, thereby allowing the cell to
lized fusion proteins eluted with glutathione prior to extensive dial-use this mechanism to target the active form of this
ysis against PBS prior to use.
enzyme selectively during cellular invasion events. How-
ever, we have not yet addressed the role of MT-MMP Purification of Autocatalytic Carboxy-Terminal
or other membrane components in the generation of Hemopexin Domain
Intact human MMP-2 was incubated with 2 mM p-aminophenyl-active MMP-2 or determined what form of this enzyme
mercuric acetate (APMA; Sigma, St. Louis, MO) for 48 hr at 378C inactually binds avb3.
collagenase buffer (50 mM Tris, 200 mM NaCl, and 10mM CaCl2 [pHOur findings illustrate a novel cell biological mecha-
7.5]). Resulting activated MMP-2 was diluted 1:1 in chromatography
nism accounting for the regulation of extracellular matrix binding buffer (25 mM Tris, 25 mM NaCl, 5 mM CaCl2, and 0.04%
remodeling, which influences cellular invasion events Brij 35 [pH 7.4]) and recirculated over a gelatin Sepharose column
critical for angiogenesis. In this case, integrin avb3 likely (Pharmacia Biotech), 103 under gravity. The column was washed
extensively with binding buffer and unbound material (containingserves two functions. First, it binds to MMP-2 facilitating
the carboxy-terminal species) was pooled and concentrated.cell-targeted collagenase activity important for cell inva-
sion (Brooks et al. 1996), which likely depends on the
Purified Receptor Binding Assayability of avb3 to bind selectively proteolyzed fragments
GST fusion proteins and full-length MMP-2 were iodinated ac-
of collagen leading to signals required for cell survival cording to the manufacturer's instructions for IODO-Beads reagent
(Montgomery et al. 1994). Second, avb3 facilitates cleav- (Pierce, Rockford, IL). Unconjugated [125I] was removed, and recov-
age of this enzyme and accumulation of a noncatalytic ered radiolabeled proteins were resuspended in PBS, quantified,
and specific activity determined. Immulon-4 multichamber stripsfragment that inhibits cell invasion. Accordingly, the ap-
(Dynatech Laboratories Inc., Chantilly, VA) were coated overnightpearance of PEX at sites of neovascularization may not
at 48C with purified integrin avb3 (50 ml/well) at 1.0 mg/ml in coatingonly serve to control normal angiogenesis or neovascu-
buffer (20 mM Tris, 150 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 1 mMlarization but, when administered exogenously, may MnCl2 [pH 7.4]). Wells were washed with PBS and blocked with
provide a therapeutic inhibitor of diseases associated 0.5% protease-free BSA in PBS (100 ml/well). Radiolabeled proteins
with angiogenesis. were diluted in collagenase binding buffer (50 mM Tris, 200 mM
NaCl, 0.05 mM CaCl2, 0.2 mM MnCl2, 0.5% protease free BSA [pH
8.0]) and added to the wells (50 ml/well) for 1 hr incubation at 378C.
Experimental Procedures Wells were washed 43 with binding buffer, separated, and binding
was quantified with a 1282 Compugamma CS Universal counter
Antibodies and Reagents (LKB Wallac, Gaithersburg, MD). Values were corrected for nonspe-
Polyclonal and monoclonal antibodies directed to MMP-2 were kind cific binding to BSA control wells.
gifts from Dr. W. G. Stetler-Stevenson (National Institute of Health, For antibody-based detection of intact MMP-2 binding to avb3,
Bethesda, MD). MAb LM609, anti-avb3 has been previously de- assays were performed essentially as described previously (Brooks
scribed (Cheresh and Spiro, 1987). MAb TV88,directed to avianPEX, et al., 1996). In brief, sterile ELISA plates (Corning Glass Works,
was generated by fusion of SP-20 myeloma cells with splenocytes Corning, NY) were coated with purified integrin avb3 (1 mg/ml) and
derived from female Balb/C mice injected intraperitoneally (6 times blocked as above before additionof inhibitors at a 23 concentration.
over 3±4 weeks) with purified recombinant chick C-terminal hemo- MMP-2 in collagenase binding buffer (final concentration 30 nM)
pexin domain (PEX) fusion protein coupled to glutathione beads. was added and incubated for 90 min at 378C. After washing, anti-
Reactive hybridomas were subcloned, and TV88 (IgG1k) was shown MMP-2 polyclonal antibody was incubated for 90 min at 378C before
to react with chick, mouse, and human forms by immunoblotting. further washing and 90 min incubation at 378C with HRP-conjugated
Recombinant chick MMP-2 was generously provided by Dr. James goat anti-rabbit secondary antibody (BioSource International, Ca-
Quigley (State University of New York at Stonybrook, Stonybrook, marillo, CA). Binding was visualized by color development with OPD
NY) and has been described previously (Aimes et al., 1994). Recom- substrate and absorbance determination at 490 nm. Optical density
binant human MMP-2 was obtained from Chemicon (Temecula, CA). values were corrected for nonspecific binding to BSA-blocked
Integrin avb3 was purified from placental tissue as described (Smith
b-casein.
et al., 1990).
[3H]-Collagen Type IV Degradation Assay
Collagen type IV degradation assays were performed as describedCell Lines
CS-1 hamster melanoma cells lacking avb3 and avb5 were provided previously, with minor modifications (Brooks et al. 1996). For cell-
mediated collagen degradation assays, 2 3 106 CS-1 or ECV304by Dr. C. Damsky (University of California, San Francisco, CA). CS-1
cells transfected with a b3 integrin subunit cDNA were described cells were preincubated for 3.5 hr at 378C with 500 ng/ml of recombi-
nant MMP-2 in a total volume of 500 ml of fibroblast basal mediumpreviously (Filardo et al., 1995). Human umbilical vein endothelial
cells ECV304 were obtained from ATCC (Rockville, MD). The avb3- (FBM) containing 0.5% protease-free BSA, 0.2 mM MnCl2, 0.1 mM
CaCl2, and 10 mg/ml Aprotinin. For inhibition experiments, PEX ornegative ECV304 cells were procured by five rounds of negative
FACS selection with MAb LM609. FHEX was included in the incubation at a concentration of 50 mg/
MMP Fragment Binds Integrin, Disrupts Angiogenesis
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ml. Cells were washed and resuspended in FBM buffer. Cells (1 3 washed four times for 30 min each in 2.5% Triton X-100 to remove
SDS and washed extensively with water. Gels were next incubated105) in 200 ml of FBM buffer were added to each [3H]-collagen type IV
(Dupont NEN, Boston, MA)±coated well incubated at 378C. Collagen for 12 hr at 378C in collagenase buffer. Gelatinolytic activity was
visualized by staining the gels with 0.5% Coomassie blue.degradation was assessed as the cpm released per 50 ml of medium
at 16 and 36 hr corrected for the cpm released from buffer-only
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